MK-0524A

Extended Release Niacin/Laropiprant · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-0524A, covering 2012-03-07 to 2014-03-14. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) [Phase 3]

See pricing